المؤلفون: Kostek, O., Hacioglu, M.B., Tastekin, D., Goksu, S.S., Alandag, C., Akagunduz, B., Karabulut, S.

مصطلحات موضوعية: Chemotherapy, Anti-VEGFtherapy, Disease controlrate, Hepatocellular carcinoma, Overallsurvival, Regorafenib, alpha fetoprotein, anthracycline, cisplatin, fluorouracil, gemcitabine, oxaliplatin, sorafenib, adult, advanced cancer, aged, alpha fetoprotein blood level, Article, cancer chemotherapy, cancer combination chemotherapy, cancer control, cancer patient, cancer survival, controlled study, drug efficacy, drug hypersensitivity, drug substitution, drug withdrawal, female, follow up

الوصف: Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the second- or third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a second- or third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (pPFS=0.22 and pOS=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. © 2020 Zerbinis Publications. All rights reserved.

العلاقة: Journal of B.U.ON.; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/37064Test; 25; 1897; 1903; 2-s2.0-85090483650; WOS:000573102800001

الإتاحة: https://hdl.handle.net/11499/37064Test

المؤلفون: Celepli P., Bigat, Ä°rem, Karabulut S., Celepli S., HücümenoÄŸlu S.

مصطلحات موضوعية: Epithelial-mesenchymal transition, Lipocalin-2, Thyroid cancer, Twist, biological marker, eosin, hematoxylin, neutrophil gelatinase associated lipocalin, transcription factor Twist, uvomorulin, vimentin, adult, aged, Article, carcinoma in situ, controlled study, epithelial mesenchymal transition, female, histopathology, human, human tissue, immunohistochemistry, lymph node metastasis, major clinical study, male, nodular hyperplasia, protein expression, thyroid adenoma, thyroid follicular carcinoma, thyroid hyperplasia

الوصف: Objective: To evaluate the expressions of lipocalin-2 (LCN-2) and Twist in thyroid cancers and examine its relationship with epithelial-to-mesenchymal transition (EMT) and clinicopathological factors. Materials and methods: The expression of LCN-2 and Twist was immunohistochemically evaluated in a total of 249 cases, including 120 patients with papillary thyroid carcinomas (PTC), 34 with follicular thyroid carcinoma (FTC), 15 with medullary thyroid carcinomas (MTC), 20 with non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 47 with follicular adenomas (FA), and 13 with nodular hyperplasia (NH). In addition, the relationship between the expression of EMT markers E-cadherin and vimentin was investigated in malignant cases. Results: A significant increase was observed in the LCN-2 and Twist expression from NH and FA to NIFTP, MTC, FTC, and PTC (p = 0.001). A high degree of LCN-2 expression was observed in the aggressive variants of PTC (p = 0.002). Twisthigh positivity was significantly higher in cases with the EMT-positive mesenchymal phenotype (p = 0.036). Conclusions: LCN-2 and Twist can be helpful diagnostic markers in the differentiation of benign and malignant thyroid nodules. Twisthigh expression supports the EMT process in thyroid cancer. LCN-2 and Twist expression may also serve as valuable predictive biomarkers in patients with thyroid cancer. In future, the determination of a LCN-2high expression in the aggressive variants of PTC may be integrated into targeted treatment strategies. © 2022 Elsevier Inc.

العلاقة: Annals of Diagnostic Pathology; Makale - Uluslararası Hakemli Dergi - Ä°dari Personel ve Öğrenci; https://hdl.handle.net/20.500.11851/8633Test; https://doi.org/10.1016/j.anndiagpath.2022.151973Test; 59; WOS:000836436500003; 2-s2.0-85129955881; Q2

الإتاحة: https://doi.org/20.500.11851/863310.1016/j.anndiagpath.2022.151973Test
https://hdl.handle.net/20.500.11851/8633Test

المؤلفون: Karabulut S., Kaya Z., Amuran G.G., Peker I., Özmen T., Gulluolu B.M., Kaya H., Erzik C., Ozer A., Akkiprik M.

المساهمون: Bayburt University, 55771646300, 55876457500, 56960629200, 56448719400, 7801655696, 57192895317, 7102340078, 23481935200, 7005139386, 57195257114

مصطلحات موضوعية: breast cancer, IGFBP5, methylation, MSP, promoter, beta actin, epidermal growth factor receptor 2, estrogen receptor, Ki 67 antigen, somatomedin binding protein 5, ERBB2 protein, human, messenger RNA, progesterone receptor, adult, age distribution, aged, Article, binding site, cancer grading, cancer prognosis, controlled study, CpG island, DNA methylation, female, gene expression regulation, gene sequence, histopathology, human tissue, lymph node metastasis

الوصف: BACKGROUND: The insulin-like growth factor binding protein5 (IGFBP5) is often dysregulated in human cancers and considered neither a tumor suppressor nor an oncogene. OBJECTIVE: We aim to examine the reason of the changeable gene regulation of IGFBP5 in the case of methylation in breast cancer. METHODS: We used methyl-specific polymerase (MSP) chain reaction to detect CpG methylation of IGFBP5 promoter and exon-I in breast cancer and adjacent tissues. Gene expression is evaluated by quantative polymerase chain reaction (qPCR). RESULTS: IGFBP5 methylation was detected in 24 of 58 (41%) and 54 of 56 (96.5%) promoter and exon-I site respectively in tumor tissues. In adjacent tissues 17 of 58 (29%) and 53 of 56 (96.5%) was methylated. IGFBP5 expression was higher estrogene receptor (ER)(+) than ER(-) patients (p = 0:0549). Beside, we found a positive correlation between the expression of IGFBP5 and G2 tumor grade (p = 0:0131). However, no correlation was observed between IGFBP5 expression and age, menopause or the presence of lymph node metastasis (p > 0:05). CONCLUSIONS: In summary, our results showed that IGFBP5 promoter and exon-I methylation did not have any differences between tumor and adjacent tissues so that IGFBP5 methylation did not change IGFBP5 gene regulation in breast cancer. This is the first study investigating the IGFBP5 gene methylation in breast cancer. © 2016 - IOS Press and the authors.

العلاقة: Breast Disease; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://dx.doi.org/10.3233/BD-160234Test; https://hdl.handle.net/20.500.12403/668Test; 36; 123; 131

الإتاحة: https://doi.org/20.500.12403/668Test
https://doi.org/10.3233/BD-160234Test
https://hdl.handle.net/20.500.12403/668Test